Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate
作者:Andrea Tarozzi、Chiara Marchetti、Benedetta Nicolini、Massimo D'Amico、Nicole Ticchi、Letizia Pruccoli、Vincenzo Tumiatti、Elena Simoni、Alessio Lodola、Marco Mor、Andrea Milelli、Anna Minarini
DOI:10.1016/j.ejmech.2016.04.002
日期:2016.7
functions of cancer cells. According to these considerations, a series of multitarget molecules have been designed by combining key structural features derived from an EGFR-TKI, PD168393, and the isothiocyanate sulforaphane. Among the obtained molecules 1–6, compound 6 emerges as a promising lead compound able to exert antiproliferative and proapoptotic effects in A431 epithelial cancer cell line by covalently
表皮生长因子受体抑制剂(EGFR-TKIs)代表了广泛用于抗癌治疗的一类化合物。越来越多的研究报道了联合疗法,其中EGFR-TK活性的阻断与其下游通路(如PI3K-Akt)的抑制有关。萝卜硫烷靶向PI3K-Akt途径,该途径的失调与癌细胞的许多功能有关。根据这些考虑,通过结合衍生自EGFR-TKI,PD168393和异硫氰酸酯萝卜硫烷的关键结构特征,设计了一系列多目标分子。在获得的分子1 - 6,化合物6 它作为一种有前途的先导化合物出现,能够通过与EGFR-TK共价结合并在不影响总Akt水平的情况下降低Akt的磷酸化,从而在A431上皮癌细胞系中发挥抗增殖和促凋亡作用。